Hundreds of thousands of people continue to die from advanced HIV, also known as AIDS, because countries are still ill-equipped to detect and treat people suffering through advanced stages of the disease, according to a new report released today by medical organisation Doctors Without Borders (MSF). Delays in responding quickly to treatment failures and interruptions jeopardise recent progress in reducing HIV deaths.
MSF calls on affected countries and donor countries to urgently deploy recommended approaches to prevent, detect and treat advanced HIV and AIDS at the community level.
The report, No Time to Lose, spans 15 countries in Africa and Asia and presents a dashboard of where countries are in terms of policies, implementation and funding to address advanced HIV, which killed 770,000 worldwide in 2018. Despite the existence of WHO guidelines since 2017 on advanced HIV, governments have been slow to include them in national guidelines, while meaningful implementation and funding lag even further behind.
The WHO guidelines recommend the roll-out of easy-to-use rapid tests to assess the status of people’s immune system (the CD4 cell count), and to diagnose the most common and deadly opportunistic infections, such as tuberculosis (TB-Lam urine test) and cryptococcal meningitis (CrAg test). These tests can deliver results in a matter of hours and, combined with proximity to patients, the days saved can make the difference between life and death for many.
Yet, MSF found that the rapid tests are almost never available at the community level, despite the fact that early detection could save many lives.
“There is no way the world will reach the target of less than 500,000 deaths from AIDS in 2020 without decisive action on dealing with retention to care, treatment interruptions and resulting mortality,” says Dr Gilles Van Cutsem, MSF Senior HIV Adviser. “In the past, the very sick patients we saw were those who did not know they had HIV. Today we see more and more people who have been treated before but stopped taking their medication and fell seriously ill, and people whose treatment stopped working.”
More than two-thirds of patients with advanced HIV that are admitted to the MSF-supported hospital in Nsanje (Malawi) arrived already very ill and have been on antiretroviral (ARV) treatment before. At MSF’s Kinshasa hospital (DRC) this figure is at 71%. Among these, more than one in four people will die because the disease was too advanced when they reached the hospital. These deaths could have been prevented.
Since MSF made the rapid tests available in health centres in Nsanje district, the number of deaths at the hospital has decreased from around 27% to less than 15%.
Only eight of the 15 countries surveyed in the report use rapid TB-LAM to test for advanced HIV patients. They are used in hospitals in South Africa, and roll-out at community level is expected. Malawi plans to roll them out to 230 health centres in 2020, and pilot programmes to introduce the test are being launched in Lesotho and Nigeria. Another pilot was recently completed in Kenya before a possible national roll out of the test.
Only a third of the countries recommend using the rapid test for Cryptococal meningitis (which accounts for 15-20% of all advanced HIV-related deaths) for patients with very weak immune systems, including Kenya, Mozambique, South Africa, South Sudan, Uganda and Zimbabwe, but most of these countries have not yet implemented that recommendation on the ground.
Currently, the TB-LAM and CrAG tests at primary healthcare level are only available in MSF-supported health centres in all 15 countries covered in the report. The global UNAIDS 90-90-90 targets (90% living with the disease knowing their status, 90% of people with living with HIV get treatment and 90% of people on treatment have undetectable virus levels in their body) assumes a succession of stages in a linear way, but the reality is that the model is circular for lots of people who need to go back to the testing, and initiating phases after having passed those stages in the past.
“We all need to accept that the job is not over once people are on treatment and doing well. We have to be there for people for the whole treatment journey, which means people’s entire lives,” says Florence Anam, MSF’s HIV/TB Advocacy Coordinator and lead author of the report. “We will not end the ravages of HIV by digging more graves, but by doing all we can to keep people healthy, no matter where they live and what their life circumstances are. They must be supported mentally and medically as close as possible to where they live.”
Some countries like Lesotho, Malawi, Kenya and Uganda have started making initial progress in advanced HIV guidelines implementation, but they will need to be supported financially. Donors should prioritise approaches to reduce mortality linked to AIDS.